Release date: 2017-11-14
Recently, Xiamen Nokang Biotech Co., Ltd. and the US Michigan State University (MSU) joint laboratory sent good news; researchers have successfully completed an artificial anti-tumor compound with high affinity to macrophage CD169 site. In preclinical studies, the antitumor compound can effectively inhibit solid tumors in an immunodeficient mouse model, and the effect is remarkable.
Through long-term studies, the compound is effective against a variety of tumors and has an inhibitory effect on tumor metastasis, and can be administered not only by injection but also by oral administration. This research has opened up a new field for the medical community to fight against human tumors and cancer ailments, with great clinical application value and broad market prospects.
Tumor is the first killer of human health! With the rapid development of science and medical technology, people have further and comprehensive understanding of the mechanism and characteristics of tumors, and researched various tumor killing methods and anti-tumor drugs. For example, various chemotherapeutic drugs developed using the characteristics of tumor metabolism higher than normal tissues; monoclonal antibodies using tumor surface specific markers, such as Herceptin. In recent years, people have begun to use the immune checkpoint inhibitors of the body's own immune system to conduct anti-tumor research, such as targeting various antibodies and small molecule inhibitors of PD1 and PDL-1. These studies have made major breakthroughs. Therapy has even been approved for clinical application and is an important development direction for future cancer treatment.
Immunotherapy mechanism based on macrophage SIGLEC1
Contrary to the above concerns of cancer treatment, the joint laboratory abandoned the inherent mainstream practice of doing articles on PD1 and PDL-1, and instead focused on macrophages. Through extensive experiments and studies, it has been found that CD169 is abundantly distributed on the surface of macrophages (also known as Siglec-1, a lectin that specifically binds to sialic acid). CD169 is highly homologous in mouse and human cells. The laboratory uses a synthetic CD169 high-affinity anti-tumor compound called sialic acid sugar (TCC-Neu5Ac). TCC-Neu5Ac can target tumors in vivo and metabolize on the surface of tumor cells to form TCC-Neu5Ac ligand.
Macrophage immune checkpoint drug M1
At the same time, the TCC-Neu5Ac ligand binds specifically to CD169 on the surface of macrophage membranes, releasing a “come toeat me†signal to macrophages, stimulating phagocytosis of macrophages, and releasing tumor fragments and presenting them. Give other immune cells an anti-tumor immune response.
Dr. Li Zhu, the head of the joint laboratory project, said: The research results have successfully completed preclinical research and applied for a patent. The preparation technology of this compound is fully mature, and is currently actively preparing for the first phase of clinical research and recruiting volunteers. . In the future, we hope that this new tumor treatment method can send more gospels to more patients, and provide new horizons and methods for humans to overcome cancer ailments.
Mechanism of action: Small molecule M1 enters the body, and because the tumor's wenberger effect mainly enters the tumor (data previously), it is metabolized to the surface of tumor cells, which is highly affinity with CD169, thereby recruiting macrophage attacks. On the one hand, macrophages phagocytose tumors, on the other hand, they present phagocytic fragments to NK, and T cells cause immune attacks.
Source: Medical Maike (WeChat emedclub_com)
Customized Drape Pack,Angiography Drape Pack,Disposable Surgical Drape Pack,Sterile Disposable Surgical Pack
ShaoXing SurgeCare Medical Products Co., Ltd. , https://www.sxsurgecaremedical.com